Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Pharmacoeconomic Aspects of Diabetes Mellitus: Outcomes and Analysis of Health Benefits Approach

Author(s): Suman Baishnab*, Ravinder Singh Jaura, Saksham Sharma, Honey Garg and Thakur Gurjeet Singh

Volume 20, Issue 8, 2024

Published on: 11 October, 2023

Article ID: e111023222039 Pages: 11

DOI: 10.2174/0115733998246567230924134603

Price: $65

Abstract

Pharmacoeconomics is an important tool for investigating and restructuring healthcare policies. In India, recent statistical studies have shown that the number of diabetic patients is rapidly increasing in the rural, middle and upper-class settings. The aim of this review is to call attention towards the need to carry out pharmacoeconomic studies for diabetes mellitus and highlight the outcome of these studies on healthcare.

A well-structured literature search from PubMed, Embase, Springer, ScienceDirect, and Cochrane was done. Studies that evaluated the cost-effectiveness of various anti-diabetic agents for type 2 diabetes were eligible for inclusion in the analysis and review. Two independent reviewers sequentially assessed the titles, abstracts, and full articles to select studies that met the predetermined inclusion and exclusion criteria for data abstraction. Any discrepancies between the reviewers were resolved through consensus.

By employing search terms such as pharmacoeconomics, diabetes mellitus, cost-effective analysis, cost minimization analysis, cost-utility analysis, and cost-benefit analysis, a total of 194 papers were gathered. Out of these, 110 papers were selected as they aligned with the defined search criteria and underwent the removal of duplicate entries.

This review outlined four basic pharmacoeconomic studies carried out on diabetes mellitus. It gave a direction that early detection, patient counseling, personalized medication, appropriate screening intervals, and early start of pharmacotherapy proved to be a cost-effective as well as health benefits approach.

[1]
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford university press 2015.
[2]
Sanchez LA. Pharmacoeconomics and formulary decision making. PharmacoEconomics 1996; 9 (Suppl. 1): 16-25.
[http://dx.doi.org/10.2165/00019053-199600091-00005] [PMID: 10160112]
[3]
Zaheer-Ud-Din B, Scahill S. Is there a role for pharmacoeconomics in developing countries? PharmacoEconomics 2010; 28(12): 1069-74.
[http://dx.doi.org/10.2165/11584890-000000000-00000] [PMID: 21080732]
[4]
NICE U. Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence (NICE) London, UK- 2013. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 (Accessedon: March 21, 2021).
[5]
CADTH. Guidelines for the economic evaluation of health technologies: Canada. Available from: www.cadth.ca/about-cadth/how-we-do-it/methods-and-guidelines/guidelines-for-the-economic-evaluation-of-health-technologies-canada (Accessed on: March 21, 2021).
[6]
Oberoi S, Oberoi A. Pharmacoeconomics guidelines: The need of hour for India. Int J Pharm Investig 2014; 4(3): 109-11.
[http://dx.doi.org/10.4103/2230-973X.138338] [PMID: 25126523]
[7]
Simpson SH, Lier DA, Majumdar SR, et al. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial. Diabet Med 2015; 32(7): 899-906.
[http://dx.doi.org/10.1111/dme.12692] [PMID: 25594919]
[8]
Starostina EG, Antsiferov M, Galstyan GR, et al. Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for Type 1 (insulin-dependent) diabetes mellitus in Moscow—blood glucose versus urine glucose self-monitoring. Diabetologia 1994; 37(2): 170-6.
[http://dx.doi.org/10.1007/s001250050089] [PMID: 8163051]
[9]
Alefan Q, Al-Issa ET, Alzoubi KH, Hammouri HM. Association of smoking with direct medical expenditures of chronic diseases in north of Jordan: a retrospective cohort study. BMJ Open 2019; 9(10): e031143.
[http://dx.doi.org/10.1136/bmjopen-2019-031143] [PMID: 31601593]
[10]
Haddix AC, Teutsch SM, Corso PS, Eds. Prevention effectiveness: a guide to decision analysis and economic evaluation. Oxford University Press 2002.
[11]
Haddix AC, Teutsch SM, Corso PS, Eds. Prevention effectiveness: a guide to decision analysis and economic evaluation. Oxford University Press 2002.
[12]
Dilokthornsakul P, Kengkla K, Saokaew S, et al. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine 2019; 37(32): 4551-60.
[http://dx.doi.org/10.1016/j.vaccine.2019.06.015] [PMID: 31280944]
[13]
Herman WH, Horblyuk R, Arondekar B, et al. PDB21 health care resource utilization and cost in type-2 diabetes patients receiving combination Sulfonylurea (Su) And Rosiglitazone (Rsg): The result trial. Value Health 2005; 8(3): 358.
[http://dx.doi.org/10.1016/S1098-3015(10)62954-3]
[14]
Costa Pinel B, Belmonte Serrano M, Páez Vives F, Sabaté Obiol A, Estopá Sánchez A, Borrás Borrás J. Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes. Pharmacoeconomic analysis of cost-effectiveness. Rev Clin Esp 2001; 201(8): 448-54.
[http://dx.doi.org/10.1016/S0014-2565(01)70877-6] [PMID: 11599156]
[15]
Tang Z, Cai W. Cost-effectiveness of pharmacogenomics-guided drug therapy. Pharmacogenomics in precision medicine: From a Perspective of Ethnic Differences. 2020; pp. 241-55.
[http://dx.doi.org/10.1007/978-981-15-3895-7_13]
[16]
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2095-128.
[http://dx.doi.org/10.1016/S0140-6736(12)61728-0] [PMID: 23245604]
[17]
Zhang N, Yang X, Zhu X, Zhao B, Huang T, Ji Q. Type 2 diabetes mellitus unawareness, prevalence, trends and risk factors: National Health and Nutrition Examination Survey (NHANES) 1999–2010. J Int Med Res 2017; 45(2): 594-609.
[http://dx.doi.org/10.1177/0300060517693178] [PMID: 28415936]
[18]
Haghdoost AA, Rezazadeh Kermani M, Sadghirad B, Baradaran HR. Prevalence of type 2 diabetes in the Islamic Republic of Iran: Systematic review and meta-analysis. East Mediterr Health J 2009; 15(3): 591-9.
[http://dx.doi.org/10.26719/2009.15.3.591]
[19]
Shah JV, Patni KN, Deshpande SS. Achieving Glycemic Control of Diabetic Patients through Clinical Pharmacist provided Counseling. Journal of Pharmaceutical Science and Bioscientific Research 2015; 5(4): 322-7.
[20]
Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach. Connecticut: Appleton and Lange 2014; 4: 141-2.
[21]
Bott OJ, Hoffmann I, Bergmann J, et al. Simulation based cost-benefit analysis of a telemedical system for closed-loop insulin pump therapy of diabetes. Stud Health Technol Inform 2006; 124: 435-40.
[PMID: 17108558]
[22]
Shah JV, Patni KN, Deshpande SS. Pharmacoeconomic evaluation, cost minimization analysis of anti-diabetic therapy in Gujarat. Int J Med Res Health Sci 2016; 5(3): 34-43.
[23]
Haycox A. Basics of economics, health economics and Pharmacoeconomics içinde Walley, T, Haycox, A, Boland, APharmacoeconomics. London: Churchill Livingstone 2004.
[24]
Rascati K. Essentials of pharmacoeconomics. Lippincott Williams & Wilkins 2013.
[25]
Gu S, Tang Z, Shi L, Sawhney M, Hu H, Dong H. Cost-minimization analysis of metformin and acarbose in treatment of type 2 diabetes. Value Health Reg Issues 2015; 6: 84-8.
[http://dx.doi.org/10.1016/j.vhri.2015.03.012] [PMID: 29698199]
[26]
Fragozo A, Puerta MF, Misas JD. Comparative analysis of insulin glargine vs. insulin detemir: A cost-minimization study applicable to Colombia. Biomédica 2015; 35(2): 204-11.
[http://dx.doi.org/10.7705/biomedica.v35i2.2338] [PMID: 26535542]
[27]
Palmer AJ, Dinneen S, Gavin JR III, Gray A, Herman WH, Karter AJ. DN2 cost-utility analysis in a UK setting of self monitoring of blood glucose in patients with type-2 DIAbetes. Value Health 2005; 8(6): A14-5.
[http://dx.doi.org/10.1016/S1098-3015(10)67184-7]
[28]
Adibe MO, Aguwa CN, Ukwe CV. Cost-utility analysis of pharmaceutical care intervention versus usual care in management of Nigerian patients with type 2 diabetes. Value Health Reg Issues 2013; 2(2): 189-98.
[http://dx.doi.org/10.1016/j.vhri.2013.06.009] [PMID: 29702864]
[29]
Dawoud D, Fenu E, Higgins B, Wonderling D, Amiel SA. Basal insulin regimens for adults with type 1 diabetes mellitus: a cost-utility analysis. Value Health 2017; 20(10): 1279-87.
[http://dx.doi.org/10.1016/j.jval.2017.05.021] [PMID: 29241887]
[30]
Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in type 2 diabetes mellitus. Diabet Med 2012; 29(3): 313-20.
[http://dx.doi.org/10.1111/j.1464-5491.2011.03429.x] [PMID: 21883438]
[31]
Gao L, Zhao FL, Li SC. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care 2012; 28(4): 436-44.
[http://dx.doi.org/10.1017/S0266462312000608] [PMID: 23006540]
[32]
Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000; 283(7): 889-96.
[http://dx.doi.org/10.1001/jama.283.7.889] [PMID: 10685713]
[33]
Ben ÂJ, Neyeloff JL, de Souza CF, et al. Cost-utility analysis of opportunistic and systematic diabetic retinopathy screening strategies from the perspective of the Brazilian public healthcare system. Appl Health Econ Health Policy 2020; 18(1): 57-68.
[http://dx.doi.org/10.1007/s40258-019-00528-w] [PMID: 31674001]
[34]
Kim SW, Kang GW. Cost-utility analysis of screening strategies for diabetic retinopathy in Korea. J Korean Med Sci 2015; 30(12): 1723-32.
[http://dx.doi.org/10.3346/jkms.2015.30.12.1723] [PMID: 26713046]
[35]
Xie X, Vondeling H. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value Health 2008; 11 (Suppl. 1): S23-32.
[http://dx.doi.org/10.1111/j.1524-4733.2008.00363.x] [PMID: 18387063]
[36]
Chien CL, Chen YC, Malone DC, Peng YL, Ko Y. Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin 2020; 36(10): 1619-26.
[http://dx.doi.org/10.1080/03007995.2020.1815686] [PMID: 32851879]
[37]
Men P, Qu S, Song Z, Liu Y, Li C, Zhai S. Lixisenatide for type 2 diabetes mellitus patients inadequately controlled on oral antidiabetic drugs: a mixed-treatment comparison meta-analysis and cost–utility analysis. Diabetes Ther 2020; 11(8): 1745-55.
[http://dx.doi.org/10.1007/s13300-020-00857-3] [PMID: 32562244]
[38]
Pollock RF, Norrbacka K, Cameron C, Mancillas-Adame L, Jeddi M. A cost–utility analysis of dulaglutide versus insulin glargine as third-line therapy for type 2 diabetes in Canada. J Comp Eff Res 2019; 8(4): 229-40.
[http://dx.doi.org/10.2217/cer-2018-0073] [PMID: 30644328]
[39]
Cloete L, Mitchell BG, Morton D. Protocol: investigating the effectiveness and cost benefit of a lifestyle intervention targeting type 2 diabetes in Australia. BMC Endocr Disord 2019; 19(1): 74.
[http://dx.doi.org/10.1186/s12902-019-0396-x] [PMID: 31307434]
[40]
Gray A, Clarke P, Farmer A, Holman R. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ 2002; 325(7369): 860.
[http://dx.doi.org/10.1136/bmj.325.7369.860] [PMID: 12386035]
[41]
Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 2000; 320(7246): 1373-8.
[http://dx.doi.org/10.1136/bmj.320.7246.1373] [PMID: 10818026]
[42]
Cavassini ACM, Lima SAM, Calderon IMP, Rudge MVC. Cost-benefit of hospitalization compared with outpatient care for pregnant women with pregestational and gestational diabetes or with mild hyperglycemia, in Brazil. Sao Paulo Med J 2012; 130(1): 17-26.
[http://dx.doi.org/10.1590/S1516-31802012000100004] [PMID: 22344355]
[43]
Haardt MJ, Selam JL, Slama G, et al. A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes. Diabetes Care 1994; 17(8): 847-51.
[http://dx.doi.org/10.2337/diacare.17.8.847] [PMID: 7956629]
[44]
Elixhauser A, Kitzmiller JL, Weschler JM. Short-term cost benefit of pre-conception care for diabetes. Diabetes Care 1996; 19(4): 384.
[http://dx.doi.org/10.2337/diacare.19.4.384a] [PMID: 8729166]
[45]
Jadhav NB, Bhosale MS, Adhav CV. Cost analysis study of oral antidiabetic drugs available in Indian market. Int J Med Res Health Sci 2013; 2(1): 63-9.
[46]
Dranitsaris G, Longo CJ, Grossman LD. The economic value of a new insulin preparation, Humalog Mix 25. Measured by a willingness-to-pay approach. PharmacoEconomics 2000; 18(3): 275-87.
[http://dx.doi.org/10.2165/00019053-200018030-00007] [PMID: 11147394]
[47]
Deng L, White AS, Pawlowska M, et al. Cost-benefit analysis of internet therapeutic intervention on patients with diabetes. Int J Endocrinol Metab 2015; 13(2): e22803.
[http://dx.doi.org/10.5812/ijem.22803] [PMID: 25926853]
[48]
Katon W, Unützer J, Fan MY, et al. Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabetes Care 2006; 29(2): 265-70.
[http://dx.doi.org/10.2337/diacare.29.02.06.dc05-1572] [PMID: 16443871]
[49]
Ji Y, Cao H, Liu Q, et al. Screening for pulmonary tuberculosis in high-risk groups of diabetic patients. Int J Infect Dis 2020; 93: 84-9.
[http://dx.doi.org/10.1016/j.ijid.2020.01.019] [PMID: 31978585]
[50]
Guillermin AL, Samyshkin Y, Wright D, Nguyen T, Villeneuve J. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. J Med Econ 2011; 14(2): 207-16.
[http://dx.doi.org/10.3111/13696998.2011.561390] [PMID: 21361858]
[51]
Gu X, Liu F, Men P, Zhai S. Cost-effectiveness analysis of liraglutide versus insulin glargine in Chinese patients with type 2 diabetes insufficiently controlled on metformin. Value Health 2018; 21: S75.
[http://dx.doi.org/10.1016/j.jval.2018.04.502]
[52]
Russo M, Bitran R, Rodriguez JC, Grassi B, Aguilera P. Cost minimization analysis of insulin glargine 300 u/ml vs. glargine 100 u/ml for the management of type 2 diabetes from a private and public third-party payer perspective in Chile. Value Health 2018; 21: S75-6.
[http://dx.doi.org/10.1016/j.jval.2018.04.506]
[53]
Napoli R, Fanelli F, Gazzi L, Larosa M, Bitonti R, Furneri G. Using 2nd generation basal insulins in type 2 diabetes: Costs and savings in a comparative economic analysis in Italy, based on the BRIGHT study. Nutr Metab Cardiovasc Dis 2020; 30(11): 1937-44.
[http://dx.doi.org/10.1016/j.numecd.2020.07.005] [PMID: 32912786]
[54]
Ravasio R, Pisarra P, Porzio R, Comaschi M. Economic evaluation of canagliflozin versus glimepiride and sitagliptin in dual therapy with metformin for the treatment of type 2 diabetes in Italy. Global & Regional Health Technology Assessment 2016; 3(2): GRHTA-5000229.
[http://dx.doi.org/10.5301/GRHTA.5000229]
[55]
Abs M, Ghae E, Rawash A, Abo Taleb A. Cost minimization analysis of u100 insulin and u40 insulin in Egyptian diabetic patients. Value Health 2014; 17(7): A745.
[http://dx.doi.org/10.1016/j.jval.2014.08.166] [PMID: 27202694]
[56]
Oksuz E, Malhan S, Urganci B, Tetik E. Cost-minimization analysis of linagliptin compared to sitagliptin in the treatment of type 2 diabetes mellitus from a Turkish healthcare perspective. J Diabetes Metab 2017; 8(5): 739.
[http://dx.doi.org/10.4172/2155-6156.1000739]
[57]
Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Eff Resour Alloc 2009; 7(1): 9.
[http://dx.doi.org/10.1186/1478-7547-7-9] [PMID: 19416529]
[58]
Henriksson F, Brandt A, Thomander L, Kielhorn A, Jansen R, Maniadakis N. PDG6: Cost-effectiveness of pioglitazone (Actos®, Takeda) in the management of type 2 diabetes mellitus in Sweden. Value Health 2001; 4(6): 504.
[http://dx.doi.org/10.1016/S1098-3015(11)71743-0]
[59]
Ikeda S, Kobayashi M. PDB2 cost-effectiveness analysis of glycemic control with pioglitazone hydrochloride for Japanese patients with type ii diabetes. Value Health 2002; 5(6): 545.
[http://dx.doi.org/10.1016/S1098-3015(10)61439-8]
[60]
Jansen R, Clausen JO, Maniadakis N, Kielhorn A, Brandt A. PDG14: an assessment of the costeffectiveness of pioglitazone (Actos*nf, Takeda) in type 2 diabetes mellitus in Denmark. Value Health 2001; 4(6): 507-8.
[http://dx.doi.org/10.1016/S1098-3015(11)71751-X]
[61]
Murthy RK, DeLong LK, Chen SC. Critical appraisal of pharmacoeconomic studies. In: Williams HC, Bigby M, Herxheimer A, Eds. Evidence-Based Dermatology.
[http://dx.doi.org/10.1002/9781118357606.ch14]
[62]
WU J. Cost-effectiveness analysis of insulin aspart 30 versus insulin glargine in patients with type 2 diabetes in China. Chung Kuo Yao Hsueh Tsa Chih 2016; 242-7.
[63]
Cookson R, Mirelman AJ, Griffin S, et al. Using cost-effectiveness analysis to address health equity concerns. Value Health 2017; 20(2): 206-12.
[http://dx.doi.org/10.1016/j.jval.2016.11.027] [PMID: 28237196]
[64]
Sun X, Guo L, Shang H, et al. The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design. Trials 2015; 16(1): 496.
[http://dx.doi.org/10.1186/s13063-015-0990-9] [PMID: 26530718]
[65]
Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014; 17(1): 5-14.
[http://dx.doi.org/10.1016/j.jval.2013.08.2291] [PMID: 24438712]
[66]
Marshall DA, Douglas PR, Drummond MF, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. PharmacoEconomics 2008; 26(6): 477-95.
[http://dx.doi.org/10.2165/00019053-200826060-00003] [PMID: 18489199]
[67]
van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy 2014; 12(1): 33-40.
[http://dx.doi.org/10.1007/s40258-013-0064-7] [PMID: 24158922]
[68]
Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010; 375(9723): 1365-74.
[http://dx.doi.org/10.1016/S0140-6736(09)62162-0] [PMID: 20356621]
[69]
Kirkizlar E, Serban N, Sisson JA, Swann JL, Barnes CS, Williams MD. Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration. Ophthalmology 2013; 120(12): 2604-10.
[http://dx.doi.org/10.1016/j.ophtha.2013.06.029] [PMID: 24084501]
[70]
Nguyen HV, Finkelstein EA, Mital S, Gardner DSL. Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for Maturity Onset Diabetes of the Young (MODY) in Singapore. J Med Genet 2017; 54(11): 747-53.
[http://dx.doi.org/10.1136/jmedgenet-2017-104670] [PMID: 28835481]
[71]
Klarenbach S, Cameron C, Singh S, Ur E. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ 2011; 183(16): E1213-20.
[http://dx.doi.org/10.1503/cmaj.110178] [PMID: 21969406]
[72]
Charokopou M, McEwan P, Lister S, et al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of type 2 diabetes mellitus. Diabet Med 2015; 32(7): 890-8.
[http://dx.doi.org/10.1111/dme.12772] [PMID: 25817050]
[73]
Gordon J, McEwan P, Evans M, Puelles J, Sinclair A. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab 2017; 19(5): 644-53.
[http://dx.doi.org/10.1111/dom.12867] [PMID: 28026911]
[74]
Zhang X, Liu S, Li Y, Wang Y, Tian M, Liu G. Long-term effectiveness and cost-effectiveness of metformin combined with liraglutide or exenatide for type 2 diabetes mellitus based on the CORE diabetes model study. PLoS One 2016; 11(6): e0156393.
[http://dx.doi.org/10.1371/journal.pone.0156393] [PMID: 27304904]
[75]
Cherla A, Renwick M, Stefanini G, Holmes DR Jr, Mossialos E. Cost‐Effectiveness of Cardiovascular, Obesity, and Diabetes Mellitus Drugs: Comparative Analysis of the United States and England. J Am Heart Assoc 2020; 9(21): e018281.
[http://dx.doi.org/10.1161/JAHA.120.018281] [PMID: 33121302]
[76]
Roberts S, Barry E, Craig D, Airoldi M, Bevan G, Greenhalgh T. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open 2017; 7(11): e017184.
[http://dx.doi.org/10.1136/bmjopen-2017-017184] [PMID: 29146638]
[77]
Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv Res 2014; 14(1): 419.
[http://dx.doi.org/10.1186/1472-6963-14-419] [PMID: 25245666]
[78]
Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N. Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes mellitus in Greece. Clin Drug Investig 2016; 36(8): 649-59.
[http://dx.doi.org/10.1007/s40261-016-0410-2] [PMID: 27221806]
[79]
Yokoyama KK, Griffin KC, Godley PJ, Cryar AK, Woodward BW. PDB9: Cost-effectiveness analysis of a multidisciplinary diabetes care clinic. Value Health 2001; 4(2): 115.
[http://dx.doi.org/10.1046/j.1524-4733.2001.40202-126.x]
[80]
Chen S, Shaheen A, Garber A. Cost-effectiveness and cost-benefit analysis of using methotrexate vs. Goeckerman therapy for psoriasis. A pilot study. Arch Dermatol 1998; 134(12): 1602-8.
[http://dx.doi.org/10.1001/archderm.134.12.1602] [PMID: 9875201]
[81]
Ozawa S, Clark S, Portnoy A, Grewal S, Brenzel L, Walker DG. Return on investment from childhood immunization in low-and middle-income countries, 2011–20. Health Aff (Millwood) 2016; 35(2): 199-207.
[http://dx.doi.org/10.1377/hlthaff.2015.1086] [PMID: 26858370]
[82]
Bloom DE, Brenzel L, Cadarette D, Sullivan J. Moving beyond traditional valuation of vaccination: Needs and opportunities. Vaccine 2017; 35 (Suppl. 1): A29-35.
[http://dx.doi.org/10.1016/j.vaccine.2016.12.001] [PMID: 28017436]
[83]
Laxminarayan R, Jamison DT, Krupnick AJ, Norheim OF. Valuing vaccines using value of statistical life measures. Vaccine 2014; 32(39): 5065-70.
[http://dx.doi.org/10.1016/j.vaccine.2014.07.003] [PMID: 25045822]
[84]
Treasury HM. The green book: Central government guidance on appraisal and evaluation Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/938046/The_Green_Book_2020.pdf (Accessed on: March 22, 2021).
[85]
Guidelines for Regulatory Impact Analysis 2016. Available from: https://aspe.hhs.gov/system/files/pdf/242926/HHS_RIAGuidance.pdf (Accessed on: March 22, 2021).
[86]
United States Environmental Protection Agency (EPA). Guidelines for Preparing Economic Analyses 2010. Available from: https://www.epa.gov/environmental-economics/guidelines-preparing-economic-analyses (Accessed on: March 22, 2021).
[87]
Elixhauser A, Weschler JM, Kitzmiller JL, et al. Cost-benefit analysis of preconception care for women with established diabetes mellitus. Diabetes Care 1993; 16(8): 1146-57.
[http://dx.doi.org/10.2337/diacare.16.8.1146] [PMID: 8375245]
[88]
Smith I, Palmer AJ, Roze S, Kennedy-Martin T. PDB3 Cost-effectiveness analysis of insulin detemir compared to nph insulin in patients with type-2 diabetes in the United Kingdom. Value Health 2004; 7(6): 735-6.
[http://dx.doi.org/10.1016/S1098-3015(10)65946-3]
[89]
Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Dobson M. Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach. PharmacoEconomics 1998; 13(3): 347-58.
[http://dx.doi.org/10.2165/00019053-199813030-00009] [PMID: 10178660]
[90]
Al-Haddad M, Ibrahim MM, Sulaiman SA, Shafie AA, Maarup N. Cost benefit analysis of the diabetes self-management program at a University Health Centre in Malaysia. J Clin Diagn Res 2010; 4: 2521-30.
[91]
Matz H, Falk M, Göttinger W, Kieselbach G. Cost-benefit analysis of diabetic eye disease. Ophthalmologica 1996; 210(6): 348-53.
[http://dx.doi.org/10.1159/000310742] [PMID: 8887393]
[92]
Taylor S, Hourihan F, Krass I, Armour C. Measuring consumer preference for models of diabetes care delivered by pharmacists. Pharm Pract (Granada) 2009; 7(4): 195-204.
[http://dx.doi.org/10.4321/S1886-36552009000400002] [PMID: 25136394]
[93]
Thomas D, Hiligsmann M, John D, Al Ahdab OG, Li H. Pharmacoeconomic Analyses and Modeling. In: Thomas D, Ed. Clinical Pharmacy Education.
[http://dx.doi.org/10.1016/B978-0-12-814276-9.00018-0]
[94]
Wolowacz S, Pearson I, Shannon P, et al. Development and validation of a cost-utility model for type 1 diabetes mellitus. Diabet Med 2015; 32(8): 1023-35.
[http://dx.doi.org/10.1111/dme.12663] [PMID: 25484028]
[95]
Zhong Y, Lin PJ, Cohen JT, Winn AN, Neumann PJ. Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence. Value Health 2015; 18(2): 308-14.
[http://dx.doi.org/10.1016/j.jval.2014.12.004] [PMID: 25773567]
[96]
Sortsø C, Green A, Jensen PB, Emneus M. Societal costs of diabetes mellitus in Denmark. Diabet Med 2016; 33(7): 877-85.
[http://dx.doi.org/10.1111/dme.12965] [PMID: 26414087]
[97]
Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011; 14(5): 665-71.
[http://dx.doi.org/10.1016/j.jval.2011.02.001] [PMID: 21839404]
[98]
Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014; 53(9): 787-800.
[http://dx.doi.org/10.1007/s40262-014-0165-y] [PMID: 25179915]
[99]
Meneghini L, Atkin SL, Gough SCL, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013; 36(4): 858-64.
[http://dx.doi.org/10.2337/dc12-1668] [PMID: 23340894]
[100]
Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013; 98(3): 1154-62.
[http://dx.doi.org/10.1210/jc.2012-3249] [PMID: 23393185]
[101]
Kadowaki T, Jinnouchi H, Kaku K, Hersløv ML, Hyllested-Winge J, Nakamura S. Efficacy and safety of once‐daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26‐week, treat‐to‐target trial. J Diabetes Investig 2016; 7(5): 711-7.
[http://dx.doi.org/10.1111/jdi.12502] [PMID: 27182031]
[102]
Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. J Med Econ 2017; 20(3): 213-20.
[http://dx.doi.org/10.1080/13696998.2016.1245663] [PMID: 27705031]
[103]
Geng J, Yu H, Mao Y, Zhang P, Chen Y. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. PharmacoEconomics 2015; 33(6): 581-97.
[http://dx.doi.org/10.1007/s40273-015-0266-y] [PMID: 25736235]
[104]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117-28.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
[105]
Nguyen E, Coleman CI, Nair S, Weeda ER. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diabetes Complications 2018; 32(2): 210-5.
[http://dx.doi.org/10.1016/j.jdiacomp.2017.10.006] [PMID: 29157870]
[106]
Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW. Health Care Cost, Quality, and Outcomes. Lawrenceville, NJ: ISPOR Book of Terms 2003.
[107]
Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313(7048): 36-9.
[http://dx.doi.org/10.1136/bmj.313.7048.36] [PMID: 8664772]
[108]
Greene WL, Concato J, Feinstein AR. Claims of equivalence in medical research: are they supported by the evidence? Ann Intern Med 2000; 132(9): 715-22.
[http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00006] [PMID: 10787365]
[109]
Span MM, TenVergert EM, van der Hilst CS, Stolk RP. Noninferiority testing in cost-minimization studies: Practical issues concerning power analysis. Int J Technol Assess Health Care 2006; 22(2): 261-6.
[http://dx.doi.org/10.1017/S0266462306051099] [PMID: 16571203]
[110]
Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care 2018; 41(5): 1009-16.
[http://dx.doi.org/10.2337/dc17-1114] [PMID: 29483185]
[111]
Torre E, Bruno GM, Di Matteo S, et al. Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes. Clinicoecon Outcomes Res 2018; 10: 413-21.
[http://dx.doi.org/10.2147/CEOR.S169045] [PMID: 30100746]
[112]
Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: A systematic review and critical analysis of the literature. Value Health 2009; 12(6): 915-22.
[http://dx.doi.org/10.1111/j.1524-4733.2009.00539.x] [PMID: 19402848]
[113]
Garg N, Arunan SK, Arora S, Kaur K. Application of mobile technology for disease and treatment monitoring of gestational diabetes mellitus among pregnant women: A systematic review. J Diabetes Sci Technol 2022; 16(2): 491-7.
[http://dx.doi.org/10.1177/1932296820965577] [PMID: 33118397]
[114]
Singh R, Kumari P, Prashar A, Sardana O, Singh V. Assessment of medication adherence among type-2 diabetes mellitus in a tertiary care hospital of North India. Environ Sci Pollut Res Int 2022; 29(17): 24951-5.
[http://dx.doi.org/10.1007/s11356-021-17434-1] [PMID: 34826085]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy